157 related articles for article (PubMed ID: 34488467)
21. OCT of Outer Retinal Hyperreflectivity, Neovascularization, and Pigment in Macular Telangiectasia Type 2.
Krivosic V; Lavia C; Aubineau A; Tadayoni R; Gaudric A
Ophthalmol Retina; 2021 Jun; 5(6):562-570. PubMed ID: 32956858
[TBL] [Abstract][Full Text] [Related]
22. Characteristics of cystoid spaces in type 2 idiopathic macular telangiectasia on spectral domain optical coherence tomography images.
Oh JH; Oh J; Togloom A; Kim SW; Huh K
Retina; 2014 Jun; 34(6):1123-31. PubMed ID: 24240556
[TBL] [Abstract][Full Text] [Related]
23. OUTER FOVEAL DEFECTS IN TYPE-2 MACULAR TELANGIECTASIA.
Chandran K; Giridhar A; Gayathri MS; Antison M; Gopalakrishnan M; Sivaprasad S
Retina; 2023 Jan; 43(1):111-119. PubMed ID: 36542082
[TBL] [Abstract][Full Text] [Related]
24. High-resolution photoreceptor imaging in idiopathic macular telangiectasia type 2 using adaptive optics scanning laser ophthalmoscopy.
Ooto S; Hangai M; Takayama K; Arakawa N; Tsujikawa A; Koizumi H; Oshima S; Yoshimura N
Invest Ophthalmol Vis Sci; 2011 Jul; 52(8):5541-50. PubMed ID: 21642620
[TBL] [Abstract][Full Text] [Related]
25. Quantitative analysis of retinal microvascular changes in macular telangiectasia type 2 using optical coherence tomography angiography.
Park YG; Park YH
PLoS One; 2020; 15(4):e0232255. PubMed ID: 32348375
[TBL] [Abstract][Full Text] [Related]
26. Multimodal Imaging of Macular Telangiectasia Type 2: Focus on Vascular Changes Using Optical Coherence Tomography Angiography.
Toto L; Di Antonio L; Mastropasqua R; Mattei PA; Carpineto P; Borrelli E; Rispoli M; Lumbroso B; Mastropasqua L
Invest Ophthalmol Vis Sci; 2016 Jul; 57(9):OCT268-76. PubMed ID: 27409482
[TBL] [Abstract][Full Text] [Related]
27. Macular Pigment Distribution as Prognostic Marker for Disease Progression in Macular Telangiectasia Type 2.
Müller S; Charbel Issa P; Heeren TFC; Thiele S; Holz FG; Herrmann P
Am J Ophthalmol; 2018 Oct; 194():163-169. PubMed ID: 30053477
[TBL] [Abstract][Full Text] [Related]
28. LONG-TERM OUTCOMES OF INTRAVITREAL BEVACIZUMAB THERAPY FOR SUBRETINAL NEOVASCULARIZATION SECONDARY TO IDIOPATHIC MACULAR TELANGIECTASIA TYPE 2.
Toygar O; Guess MG; Youssef DS; Miller DM
Retina; 2016 Nov; 36(11):2150-2157. PubMed ID: 27258671
[TBL] [Abstract][Full Text] [Related]
29. Prevalence and Severity of Diabetic Retinopathy in Patients with Macular Telangiectasia Type 2.
van Romunde SHM; van der Sommen CM; Martinez Ciriano JP; Vingerling JR; Yzer S
Ophthalmol Retina; 2021 Oct; 5(10):999-1004. PubMed ID: 33444807
[TBL] [Abstract][Full Text] [Related]
30. Different types of macular telangiectasia in two eyes of a patient.
Venkatesh R; Reddy NG; Pereira A; Yadav NK; Chhablani J
Eur J Ophthalmol; 2022 Sep; 32(5):NP9-NP12. PubMed ID: 33960244
[TBL] [Abstract][Full Text] [Related]
31. Does size of telangiectasia on optical coherence tomography angiography influence vision in eyes with type 2 macular telangiectasia?
Kelkar AS; Kelkar JA; Tidke S; Agarwal A; Bolisetty M; Kelkar S
Indian J Ophthalmol; 2021 Dec; 69(12):3570-3576. PubMed ID: 34826997
[TBL] [Abstract][Full Text] [Related]
32. Microvascular changes precede visible neurodegeneration in fellow eyes of patients with asymmetric type 2 macular telangiectasia.
Chandran K; Giridhar A; Gopalakrishnan M; Sivaprasad S
Eye (Lond); 2022 Aug; 36(8):1623-1630. PubMed ID: 34326496
[TBL] [Abstract][Full Text] [Related]
33. Choroidal vascularity index: an enhanced depth optical coherence tomography-based parameter to determine vascular status in patients with proliferative and non-proliferative macular telangiectasia.
Karasu B; Celebi ARC
Int Ophthalmol; 2021 Oct; 41(10):3505-3513. PubMed ID: 34181193
[TBL] [Abstract][Full Text] [Related]
34. Multicolor imaging in macular telangiectasia-a comparison with fundus autofluorescence.
Govindahari V; Fraser-Bell S; Ayachit AG; Invernizzi A; Nair U; Nair DV; Lupidi M; Singh SR; Rajendran A; Zur D; Gallego-Pinazo R; Marco RD; Cagini C; Cozzi M; Chhablani J
Graefes Arch Clin Exp Ophthalmol; 2020 Nov; 258(11):2379-2387. PubMed ID: 32803329
[TBL] [Abstract][Full Text] [Related]
35. EFFICACY OF INTRAVITREAL AFLIBERCEPT IN MACULAR TELANGIECTASIA TYPE 1 IS LINKED TO THE OCULAR ANGIOGENIC PROFILE.
Kowalczuk L; Matet A; Dirani A; Daruich A; Ambresin A; Mantel I; Spaide RF; Turck N; Behar-Cohen F
Retina; 2017 Dec; 37(12):2226-2237. PubMed ID: 28002269
[TBL] [Abstract][Full Text] [Related]
36. Distribution of macular pigments in macular telangiectasia type 2 and correlation with optical coherence tomography characteristics and visual acuity.
Srinivasan R; Teussink MM; Sloan KR; Bharat RPK; Narayanan R; Raman R
BMC Ophthalmol; 2022 Jun; 22(1):264. PubMed ID: 35698056
[TBL] [Abstract][Full Text] [Related]
37. Long term follow-up of visual acuity and incidence of subretinal neovascularization in Mactel Type 2 in 82 Eyes.
Marsonia K; Kiran Chandra K; Ali MH; Chhablani J; Narayanan R
Semin Ophthalmol; 2022 Feb; 37(2):136-141. PubMed ID: 34027801
[TBL] [Abstract][Full Text] [Related]
38. Functional Relevance of Hyper-Reflectivity in Macular Telangiectasia Type 2.
Tzaridis S; Friedlander M;
Invest Ophthalmol Vis Sci; 2021 Mar; 62(3):6. PubMed ID: 33661283
[TBL] [Abstract][Full Text] [Related]
39. Right-angled vessels in macular telangiectasia type 2.
Tzaridis S; Heeren T; Mai C; Thiele S; Holz FG; Charbel Issa P; Herrmann P
Br J Ophthalmol; 2021 Sep; 105(9):1289-1296. PubMed ID: 30808615
[TBL] [Abstract][Full Text] [Related]
40. CORRELATION OF CLINICAL AND STRUCTURAL PROGRESSION WITH VISUAL ACUITY LOSS IN MACULAR TELANGIECTASIA TYPE 2: MacTel Project Report No. 6-The MacTel Research Group.
Peto T; Heeren TFC; Clemons TE; Sallo FB; Leung I; Chew EY; Bird AC
Retina; 2018 Jan; 38 Suppl 1(Suppl 1):S8-S13. PubMed ID: 28505012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
